Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 134 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: End Stage Renal Disease on Hemodialysis (Diagnosis) Clear all
Completed Phase 1 Interventional

A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment

NCT02902679
View directory record Official record
Conditions
Thrombosis, Factor XI, Renal Impairment, ESRD (End-Stage Renal Disease)
Interventions
BMS-986177
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 23, 2026, 1:13 PM EDT
Completed Not applicable Interventional

The Effects of Laughter Therapy on Hemodialysis on Depression

NCT04098627
View directory record Official record
Conditions
End Stage Kidney Disease
Interventions
Laughter Therapy
Behavioral
Lead sponsor
Satellite Healthcare
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Oct 23, 2026, 1:13 PM EDT
Withdrawn Phase 4 Interventional

A Study in Patients With Fabry Disease Who Are on Chronic Hemodialysis Therapy for Treatment of End-stage Renal Insufficiency.

NCT00312767
View directory record Official record
Conditions
Fabry Disease
Interventions
Fabrazyme (agalsidase beta)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
North Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2014 · Synced Oct 23, 2026, 1:13 PM EDT
Completed Phase 2 Interventional Results available

Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment

NCT01414075
View directory record Official record
Conditions
Dialysis, Anemia
Interventions
Roxadustat, Oral Iron, IV Iron
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Northridge, California • Yuba City, California • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 1, 2021 · Synced Oct 23, 2026, 1:13 PM EDT
Terminated Phase 2 Interventional

A Phase 2A Trial of FMX-8 Treatment for Anemia in Patients With ESRD on Hemodialysis HD

NCT01873534
View directory record Official record
Conditions
Anemia of Chronic Disease
Interventions
FMX-8
Drug
Lead sponsor
FerruMax Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Arvada, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 11, 2015 · Synced Oct 23, 2026, 1:13 PM EDT
Completed Phase 3 Interventional

Zemplar® Capsule in Reducing Serum Intact Parathyroid Hormone Levels in Chronic Kidney Disease Stage 5 Subjects on Hemodialysis or Peritoneal Dialysis

NCT00091975
View directory record Official record
Conditions
Kidney Disease
Interventions
Zemplar Capsule
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
16
States / cities
San Diego, California • Washington D.C., District of Columbia • Fort Meyers, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2011 · Synced Oct 23, 2026, 1:13 PM EDT
Terminated Not applicable Interventional

The Effect of Nighttime Dialysis on the Inflammation of Kidney Failure

NCT00234130
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
nocturnal vs conventional dialysis
Procedure
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2009 · Synced Oct 23, 2026, 1:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on Hemodialysis

NCT01340586
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Apixaban
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 11, 2016 · Synced Oct 23, 2026, 1:13 PM EDT
Completed Not applicable Interventional Results available

Motivational Strategies To Empower African Americans To Improve Dialysis Adherence

NCT05003115
View directory record Official record
Conditions
End Stage Renal Disease on Dialysis
Interventions
Motivational interviewing
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 23, 2026, 1:13 PM EDT
Completed No phase listed Observational

EXtension of Tablo TrEatmeNt Duration Registry

NCT04912050
View directory record Official record
Conditions
End Stage Renal Disease (ESRD), End Stage Renal Disease on Dialysis, Acute Kidney Injury
Interventions
Tablo Hemodialysis System
Device
Lead sponsor
Outset Medical
Industry
Eligibility
Not listed
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 12, 2022 · Synced Oct 23, 2026, 1:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis

NCT05624723
View directory record Official record
Conditions
Renal Insufficiency, Kidney Diseases
Interventions
INCB054707
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 82 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Oct 23, 2026, 1:13 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Pilot Trial of Twice-weekly Versus Thrice-weekly Hemodialysis in Patients With Incident End-stage Kidney Disease

NCT03740048
View directory record Official record
Conditions
End Stage Renal Failure on Dialysis
Interventions
Hemodialysis, Patiromer Oral Product
Other · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 23, 2026, 1:13 PM EDT
Completed Not applicable Interventional Results available

Ultrafiltration Profiling and Outcomes Among Individuals on Maintenance Hemodialysis

NCT03301740
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
UF profiling during HD, Conventional HD
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 85 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Carrboro, North Carolina • Siler City, North Carolina
Source: ClinicalTrials.gov public record
Updated May 15, 2020 · Synced Oct 23, 2026, 1:13 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis

NCT02273726
View directory record Official record
Conditions
CKD Anemia in Stable Dialysis Patients
Interventions
Epoetin Alfa, Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
74
States / cities
Phoenix, Arizona • Pine Bluff, Arkansas • Chula Vista, California + 58 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 23, 2026, 1:13 PM EDT
Completed Phase 2 Interventional

A Clinical Study to Assess the Safety of PEG-Hirudin (SPP200) Compared to Heparin in Patients Who Are on Haemodialysis

NCT00074620
View directory record Official record
Conditions
Chronic Kidney Failure, Vascular Graft Occlusion
Interventions
PEG-hirudin
Drug
Lead sponsor
Speedel Pharma Ltd.
Industry
Eligibility
21 Years to 75 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2007 · Synced Oct 23, 2026, 1:13 PM EDT
Completed Phase 4 Interventional Results available

Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5

NCT02392208
View directory record Official record
Conditions
End-Stage Renal Disease, Stage 5 Chronic Kidney Disease
Interventions
Telavancin, Pharmacokinetic Blood Sampling
Drug · Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 23, 2026, 1:13 PM EDT
Completed Phase 1 Interventional

Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease

NCT01978587
View directory record Official record
Conditions
Anemia in Chronic Kidney Disease
Interventions
JTZ-951
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 23, 2026, 1:13 PM EDT
Terminated Phase 3 Interventional Results available

The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis

NCT00503698
View directory record Official record
Conditions
Chronic Kidney Disease, End-Stage Renal Disease
Interventions
somatropin, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
209
States / cities
Alexander City, Alabama • Birmingham, Alabama • Madison, Alabama + 177 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 23, 2026, 1:13 PM EDT
Completed No phase listed Observational

Oxidative Stress and Hemodialysis Access Failure

NCT00410449
View directory record Official record
Conditions
End Stage Renal Disease, Hemodialysis
Interventions
Alpha tocopherol
Drug
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced Oct 23, 2026, 1:13 PM EDT
Completed Phase 3 Interventional

Evaluation of Manufacturing Lot of StaphVAX

NCT00211900
View directory record Official record
Conditions
Staphylococcal Infections, Chronic Kidney Failure
Interventions
S. aureus Type 5 & 8 Capsular Polysaccharide Vaccine
Biological
Lead sponsor
Nabi Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Madison, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 4, 2008 · Synced Oct 23, 2026, 1:13 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis

NCT03963895
View directory record Official record
Conditions
End Stage Renal Disease, Thrombosis
Interventions
AB002 Dose 1, AB002 Dose 2, placebo
Drug
Lead sponsor
Aronora, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Oct 23, 2026, 1:13 PM EDT
Completed Phase 3 Interventional

Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2

NCT05836220
View directory record Official record
Conditions
Secondary Hyperparathyroidism, End Stage Kidney Disease
Interventions
PLS240, Placebo, Open-Label Extension PLS240
Drug
Lead sponsor
Pathalys Pharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
50
States / cities
Anaheim, California • Chula Vista, California • Escondido, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 23, 2026, 1:13 PM EDT
Terminated Phase 2 Interventional Results available

A Safety Study of Pentoxifylline for the Treatment of Anemia

NCT01102218
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Erythropoietin, Pentoxifylline
Drug
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Chicago, Illinois • Kalamazoo, Michigan • Brookhaven, Mississippi + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2012 · Synced Oct 23, 2026, 1:13 PM EDT